Clinical trials: GIST
Pancreatic Cancer, Gastrointestinal Neoplasms
Permission to Collect Blood Over Time for Research
To determine whether biomarkers assessed in blood samples can be used to detect individuals at risk for developing blood clots or worsening of their underlying disease.
- Conditions
- Pancreatic Cancer, Gastrointestinal Neoplasms, Colon Rectal Cancer Adenocarcinoma, Esophageal Cancer
- Trial name
- NCT00767234
- Testing
- Observation
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Stanford University
GIST
A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
The purpose of this study is to evaluate the efficacy and safety of ponatinib in participants with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure of prior tyrosine kinase inhibitor (TKI)…
- Trial name
- GIST (NCT01874665)
- Testing
- Ponatinib
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- Ariad Pharmaceuticals
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Gastrointestinal Cancer
Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)
The goal of this clinical research study is to learn if Tasigna® (nilotinib) can cause tumor cells to shrink and/or die in patients with GIST who are scheduled for surgery or may be eligible for surgery.
- Trial name
- NCT01270893
- Testing
- Nilotinib
- Sponsor
- M.D. Anderson Cancer Center
Gastrointestinal Stromal Tumors, GIST
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
- Trial name
- NCT06208748
- Testing
- Bezuclastinib in combination with sunitinib
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Gastrointestinal Neoplasms
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug…
- Trial name
- NCT07218926
- Testing
- IDRX-42, Sunitinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Paraganglioma, Gastrointestinal Stromal Tumors
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
Background: Wild-type gastrointestinal stromal tumor (GIST) is a cancer in the esophagus, stomach, or intestines. It does not respond well to standard chemotherapy or radiation therapy.
- Conditions
- Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms
- Trial name
- NCT03165721
- Testing
- SGI-110 (guadecitabine)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumor
Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
Gastrointestinal stromal tumors (GISTs) are a form of sarcoma and the most common sarcoma tumors of the gastrointestinal tract. The limited clinical experience suggests that GIST patients may benefit from neo-adjuvant therapy…
- Trial name
- NCT01865565
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Chang Gung Memorial Hospital
Progressive Sarcoma
Treatment of Patients With RAD001 With Progressive Sarcoma
The purpose of this multicenter, three-arm, exact binomial single-stage, phase II trial is to determine the preliminary efficacy and safety of RAD001 in patients with histological evidence of progressive or metastatic bone or…
- Trial name
- NCT00767819
- Testing
- Everolimus
- Where
- 6 sites in Germany, Italy
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Stromal Tumor
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Phase II trial to study the effectiveness of neoadjuvant and adjuvant imatinib mesylate in treating patients who are undergoing surgery for primary or recurrent malignant gastrointestinal stromal tumor.
- Trial name
- NCT00028002
- Testing
- Conventional Surgery, Imatinib Mesylate
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
GIST, Gastrointestinal Stromal Tumors
Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
The purpose of this trail is to evaluate the performance of Genetron D842V PCR kit in GIST patients using real-time PCR method.
- Trial name
- NCT05400018
- Where
- 3 sites in China
- Volunteers
- 1,041 people
- Sponsor
- Genetron Health
Gastrointestinal Stromal Tumors
Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
The aim of this trial is to evaluate the safety of laparoscopic resection for GIST whose diameter is ≥2cm and ≤5cm at unfavorable anatomic sites of stomach.
- Trial name
- NCT05197933
- Testing
- Laparoscopic resection
- Where
- China
- Volunteers
- 182 people
- Sponsor
- RenJi Hospital
Gastrointestinal Stromal Tumors
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
With discovery of KIT mutations and the advent of KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), there has been substantial improvement in overall survival in patients with advanced and/or metastatic…
- Trial name
- NCT02607332
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Oblimersen may help imatinib mesylate kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00091078
- Testing
- oblimersen sodium, imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Gastrointestinal Stromal Tumor
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
This is an observational study in which data already collected from people with advanced gastrointestinal stromal tumors are studied.
- Trial name
- NCT06321055
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Bayer
Gastric GIST, Submucosal Tumor of Stomach
Laparoscopic Management of Gastrointestinal Stromal Tumor of Stomach
Gastric GISTs are rare neoplasms that require excision for cure. Although the feasibility of laparoscopic resection of gastric GIST less than 2cms has been established, the feasibility, safety and long-term efficacy of these…
- Trial name
- NCT03722056
- Testing
- Laparoscopic resection
- Volunteers
- 42 people
- Sponsor
- GEM Hospital & Research Center
Gastrointestinal Stromal Tumors
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
- Trial name
- NCT01275222
- Testing
- RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib)
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Progression-free Survival, Gastrointestinal Stromal Tumor
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved.
- Conditions
- Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
- Trial name
- ZJGIST-01 (NCT04933669)
- Testing
- Imatinib
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Liquid Tumor, Cancer
GIST in Hematopoietic Stem Cell Transplantation/Bone Marrow Transplantation
The purpose of this study is to assess the efficacy of using GIST language when speaking to patients about bone marrow and hematopoietic stem cell transplantation.
- Conditions
- Liquid Tumor, Cancer, Psychological Feedback
- Trial name
- NCT03959046
- Testing
- GIST
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
This phase II MATCH treatment trial tests how well sunitinib in treating patients with cancer that has certain genetic changes. Sunitinib is in a class of medications called kinase inhibitors.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390826
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)